Cargando…

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy

BACKGROUND: With the rising number of chimeric antigen receptor (CAR) T cell treated patients, it is increasingly important to understand the treatment’s impact on patient-reported outcomes (PROs) and, ideally, identify biomarkers of central nervous system (CNS) adverse effects. METHODS: The purpose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knight, Jennifer M., Szabo, Aniko, Arapi, Igli, Wu, Ruizhe, Emmrich, Amanda, Hackett, Edward, Sauber, Garrett, Yim, Sharon, Johnson, Bryon, Hari, Parameswaran, Schneider, Dina, Dropulic, Boro, Cusatis, Rachel N., Cole, Steve W., Hillard, Cecilia J., Shah, Nirav N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098435/ https://www.ncbi.nlm.nih.gov/pubmed/35603278 http://dx.doi.org/10.1038/s43856-022-00116-5

Ejemplares similares

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes
por: Knight, Jennifer M., et al.
Publicado: (2022)

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response
por: Zurko, Joanna, et al.
Publicado: (2021)

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA
por: Shah, Nirav N, et al.
Publicado: (2023)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

Gut microbiome and CAR-T therapy
por: Abid, Muhammad Bilal, et al.
Publicado: (2019)

A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
por: Bari, Rafijul, et al.
Publicado: (2019)

Corrigendum: A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
por: Bari, Rafijul, et al.
Publicado: (2019)

Advances in Lentiviral Vector-based Cell Therapy with Mesenchymal Stem Cells
por: Baranyi, Lajos, et al.
Publicado: (2012)

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol
por: Johnson, Alexander K., et al.
Publicado: (2022)

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy
por: Furqan, Fateeha, et al.
Publicado: (2022)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen
por: Palmen, Breanna, et al.
Publicado: (2023)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease
por: Drobyski, William R., et al.
Publicado: (2018)

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
por: Schneider, Dina, et al.
Publicado: (2017)

Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up
por: Migrino, Raymond Q, et al.
Publicado: (2009)

Erratum in Volume LV
Publicado: (1841)

Institution Building: LV Prasad Eye Institute
por: Rao, Gullapalli N
Publicado: (2022)

3D Strain helps relating LV function to LV and structure in athletes
por: Stefani, Laura, et al.
Publicado: (2014)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
por: Alabanza, Leah M., et al.
Publicado: (2022)

For LV pacing, four is greater than two
por: Reynolds, Matthew R., et al.
Publicado: (2017)

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
por: Schneider, Dina, et al.
Publicado: (2018)

Embolised ASD device in LV
por: Raut, Monish S., et al.
Publicado: (2016)

Dr. Lothrop.—Volume LV
Publicado: (1899)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023)

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial
por: D'Souza, Anita, et al.
Publicado: (2020)

Cytokines in CAR T Cell–Associated Neurotoxicity
por: Gust, Juliane, et al.
Publicado: (2020)

The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation
por: Taylor, Mallory R., et al.
Publicado: (2022)

SCT LV3 Card Manual
por: Stastny, J
Publicado: (2004)

Getting the LV lead to the right spot
por: Jackson, K.P., et al.
Publicado: (2015)

The use of Apixaban for the treatment of an LV thrombus
por: Bennett, Sadie, et al.
Publicado: (2018)

Subclinical LV Dysfunction Detection Using Speckle Tracking Echocardiography in Hypertensive Patients with Preserved LV Ejection Fraction
por: Ayoub, Amal Mohamed, et al.
Publicado: (2016)

Elevated LV Mass and LV Mass Index Sign on the Athlete’s ECG: Athletes’ Hearts are Prone to Ventricular Arrhythmia
por: Yılmaz, Mücahid, et al.
Publicado: (2018)

LV Pseudoaneurysm With Concomitant Mitral Valve Defect After LV Summit Ablation: A Rare Late Complication
por: Darma, Angeliki, et al.
Publicado: (2021)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Hyperinsulinemia improves ischemic LV function in insulin resistant subjects
por: Heck, Patrick M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9b6lmlgjg7i1qekps2elratmrv